Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05844228 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
A Phase 1 study, sponsored by Vir Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05844228 is a Phase 1 study that has completed, run by Vir Biotechnology. The registered enrollment target is 28 participants.
The verdict
NCT05844228, a Phase 1 study, has completed, sponsored by Vir Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable
Interventions
- DRUG VIR-2218
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2025-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05844228
The ClinicalTrials.gov registry entry for NCT05844228 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vir Biotechnology, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VIR-2218 is the first listed.
NCT05844228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05844228 about?
NCT05844228 is a clinical study titled "A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218". The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable
What is the current status of trial NCT05844228?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-06-01. Estimated completion is 2025-04-21.
What interventions are being tested in trial NCT05844228?
The interventions under investigation include: VIR-2218 (DRUG).
Who is sponsoring clinical trial NCT05844228?
This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.